Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Santa Maria Da Feira – page 20

637 clinical trials in Santa Maria Da Feira, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Santa Maria Da Feira at a glance
637
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

637 trials in Santa Maria Da Feira

Open in trial search

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Cardiac failure acute+1

Not yet recruiting

Efficacy of istaroxime versus placebo (sodium chloride) infusion in patients with cardiogenic shock due to acute heart failure

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Istaroxime
  • Sponsor:Seismic Pharmaceuticals Operations LLC

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Conjunctivitis allergic+1

Not yet recruiting

Efficacy and safety of Depigoid Olea 1000 DPP/ml compared with placebo in patients with moderate to severe allergic rhinoconjunctivitis due to olive pollen

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:LETI Pharma S.L.U.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:GSK5733584
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Santa Maria Da Feira

What the registry says about research in the country

01 Neurological Disorders

Ongoing research evaluating novel treatments for multiple sclerosis and epilepsy, with studies focusing on both relapsing and progressive forms of MS, as well as various types of seizure disorders.

  • Multiple Sclerosis Treatments
  • Epilepsy Management
  • Seizure Control Studies

Multiple trials testing new compounds like tolebrutinib and fenebrutinib for long-term disease management.

02 Cardiovascular Health

Studies focusing on preventing cardiovascular events and managing atherosclerotic disease, with particular attention to high-risk patients and post-stroke care.

  • Stroke Prevention
  • Heart Attack Prevention
  • Atrial Fibrillation Management

Innovative therapies being tested to reduce major adverse cardiovascular events and improve patient outcomes.

03 Inflammatory Conditions

Research targeting inflammatory bowel diseases, including studies on Crohn's Disease and ulcerative colitis, testing new therapeutic approaches.

  • Gastrointestinal Disorders
  • Nasal Polyps Treatment
  • Autoimmune Conditions

Evaluating combination therapies and novel compounds for moderate to severe disease states.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.